All studies
Phase 3RecruitingInterventionalNCT07276399

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5)

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Squamous Cell Carcinoma of Head and Neck
I want to take partRefer a patient6 sites in India · 205 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Janssen Research & Development, LLC
Enrolment target
600
Started
3 December 2025
Main results due (estimated)
18 June 2029
Study ends (estimated)
18 July 2029
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
None
Sites
205 · 6 in India
First posted
11 December 2025
Registry updated
3 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion criteria:

* Be more than or equal to (\>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater)
* Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location; c. Must have documented local testing results per local regulations; d. Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative
* Be treatment-naive for systemic therapy in the R/M setting
* Have an ECOG performance status of 0 or 1
* Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1

Exclusion criteria:

* Have an uncontrolled illness
* Have untreated brain metastases or history of known presence of leptomeningeal disease
* Have a history of clinically significant cardiovascular disease
* Inadequate organ or bone marrow function
* Known allergies, hypersensitivity, contraindications, or intolerance to excipients of: Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU and Hyaluronidase

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.

What participants receive

  • Experimental

    Arm A: Pembrolizumab, Amivantamab, Carboplatin

    Participants will receive pembrolizumab, amivantamab and carboplatin.

    Biological: Amivantamab · Biological: Pembrolizumab · Drug: Carboplatin

  • Active comparator

    Arm B: Pembrolizumab, 5-Flurouracil (5-FU), Carboplatin or Cisplatin

    Participants will receive pembrolizumab, 5-FU and carboplatin or cisplatin (platinum therapy).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: 5-Flurouracil · Drug: Cisplatin

Interventions

  • AmivantamabBiological

    Also known as JNJ-61186372, RYBREVANT

    Amivantamab will be administered.

  • PembrolizumabBiological

    Pembrolizumab will be administered.

  • CarboplatinDrug

    Carboplatin will be administered.

  • 5-FlurouracilDrug

    5-Flurouracil will be administered for over 4-day infusion period.

  • CisplatinDrug

    Cisplatin will be administered.

What the study measures

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 3 years 7 months

  2. Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

    ORR is defined as the percentage of randomized participants achieving a confirmed best overall response (BOR) of partial response (PR) or complete response (CR) by BICR using RECIST version 1.1 .

    Time frame: Up to approximately 3 years 7 months

Secondary outcomes

  1. Progression-Free Survival (PFS) Using RECIST Version 1.1, as Assessed by BICR

    PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, based on BICR assessment using RECIST v1.1, regardless of treatment discontinuation or start of subsequent anticancer therapy.

    Time frame: Up to approximately 3 years 7 months

  2. Duration of Response (DOR) As Assessed by BICR

    DOR as assessed by BICR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as best response.

    Time frame: Up to approximately 3 years 7 months

  3. ORR as Assessed by Investigator

    ORR as assessed by the investigator is defined as the percentage of randomized participants achieving CR or PR, as defined by investigator assessment using RECIST v1.1 criteria.

    Time frame: Up to approximately 3 years 7 months

  4. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy, whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy or any AE that is considered treatment-related regardless of the start date of the event.

    Time frame: Up to approximately 3 years 7 months

  5. Number of Participants with Laboratory Abnormalities

    Blood samples will be collected to determine the laboratory (serum chemistry and hematology) abnormalities.

    Time frame: Up to approximately 3 years 7 months

  6. Percentage of Participants with Improved or Stable Symptoms Compared to Baseline as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module 43 (EORTC QLQ-HN43) Symptom Scale Score

    EORTC QLQ-HN43, is a self-administered, 43-item questionnaire measuring the health-related quality of life (HRQoL) of participants with head and neck cancer. EORTC QLQ-HN43 includes 19 scales (anxiety, body image, coughing, dry mouth and sticky saliva, neurological problems, opening mouth, pain in the mouth, social contact, problems with senses, shoulder problems, skin problems, swelling in the neck, social eating, speech, swallowing, sexuality, problems with teeth, weight loss, and problems with wound healing). Responses to items are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Higher scores indicate worse health outcomes.

    Time frame: Baseline, up to approximately 3 years 7 months

  7. Percentage of Participants with Improved or Stable Symptoms Compared to Baseline as Measured by EORTC QLQ-Core (C) 30 Symptom Scale Score

    EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 3 symptom scales (fatigue, pain, and nausea and vomiting), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.

    Time frame: Baseline, up to approximately 3 years 7 months

  8. Change from Baseline in Functioning HRQoL, as Measured by Functioning Scales of the EORTC QLQ-C30

    EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.

    Time frame: Baseline, up to approximately 3 years 7 months

  9. Change from Baseline in Overall HRQoL, as Measured by Global Health Scales of the EORTC QLQ-C30

    EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.

    Time frame: Baseline, up to approximately 3 years 7 months

  10. Differences Between Treatment Groups (Arms A and B) for EORTC Quality of Life (QLG) Item Library-46 (IL-46) Tolerability Scale Scores

    EORTC IL46 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Higher score indicates more impact of treatment side-effects.

    Time frame: Up to approximately 3 years 7 months

  11. Serum Concentration of Amivantamab

    Serum concentrations of amivantamab will be analyzed.

    Time frame: Up to approximately 3 years 7 months

  12. Number of Participants with Serum Anti-Amivantamab Antibodies

    Participants who are positive to serum anti-amivantamab antibodies will be reported.

    Time frame: Up to approximately 3 years 7 months

Who is running it

Lead sponsor
Janssen Research & Development, LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Janssen Research & Development, LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
61186372HNC3001
Other IDs
61186372HNC3001, 2025-521917-24-00, 2025
  • Janssen Research & Development, LLC Clinical Trial

    Study director

    Janssen Research & Development, LLC

Study sites(205)

  • Apollo Speciality Hospital, Chennai

    Chennai, India

    Recruiting

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, India

    Recruiting

  • Chittaranjan National Cancer Institute (CNCI)

    Kolkata, India

    Recruiting

  • HealthCare Global HCG Manavata Cancer Centre

    Nashik, India

    Recruiting

  • All India Institute of Medical Sciences

    New Delhi, India

    Recruiting

  • Kailash Cancer Hospital and Research Centre

    Vadodara, India

    Recruiting

  • Ironwood Cancer and Research Center

    Chandler, Arizona, United States

    Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona, United States

    Recruiting

  • Providence St Jude Medical Center

    Fullerton, California, United States

    Recruiting

  • Scripps Health

    La Jolla, California, United States

    Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California, United States

    Recruiting

  • University of California, Los Angeles UCLA

    Los Angeles, California, United States

    Recruiting

  • Valkyrie Clinical Trials Murrieta

    Murrieta, California, United States

    Recruiting

  • University Of California - Davis

    Sacramento, California, United States

    Recruiting

  • UCSF Medical Center at Mission Bay

    San Francisco, California, United States

    Recruiting

  • Stanford University Medical Center

    Stanford, California, United States

    Recruiting

  • Hartford Hospital

    Hartford, Connecticut, United States

    Recruiting

  • Yale Cancer Center

    New Haven, Connecticut, United States

    Recruiting

  • Florida Cancer Specialists South

    Fort Myers, Florida, United States

    Recruiting

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, United States

    Recruiting

  • AdventHealth Medical Group Oncology and Hematology at Orlando

    Orlando, Florida, United States

    Recruiting

  • Florida Cancer Specialists North Region

    St. Petersburg, Florida, United States

    Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida, United States

    Recruiting

  • Emory University

    Atlanta, Georgia, United States

    Recruiting

  • Central Georgia Cancer Care

    Macon, Georgia, United States

    Recruiting

  • Rush University Medical Center Rush University Cancer Center Chicago

    Chicago, Illinois, United States

    Recruiting

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois, United States

    Recruiting

  • Cancer Care Specialists of Central Illinois

    O'Fallon, Illinois, United States

    Recruiting

  • University of Kentucky Medical Center

    Lexington, Kentucky, United States

    Recruiting

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, United States

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Recruiting

  • Trinity Health St Joseph Mercy Ann Arbor

    Ann Arbor, Michigan, United States

    Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan, United States

    Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri, United States

    Recruiting

  • NHO Revive Research Institute, LLC

    Lincoln, Nebraska, United States

    Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, United States

    Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York, United States

    Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York, United States

    Recruiting

  • Montefiore Medical Center

    The Bronx, New York, United States

    Recruiting

  • Bronx Veterans Affairs Medical Center

    The Bronx, New York, United States

    Recruiting

Showing 40 of 205 sites. 205 recruiting, 0 not recruiting and 0 cancelled; 6 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Source: ClinicalTrials.gov record NCT07276399, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.